RPID · Rapid Micro Biosystems, Inc.
Market Cap
$61.70M
Shares
50.16M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.23
Open$1.22
Day$1.20–1.26
52W close$1.20–4.68
Avg vol 30d242K
Short int869K · 1.7% float · 4.5d
Short vol81%
Last earningsAug 7, 2026
DataJul 2021–Sep 2026
Filing10-Q · Aug 7
Up next
Next earnings call
Nov 2, 2026
Est · unconfirmed
· in 7 wks
filed Aug 7, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$35.18M
Trailing 12 months
Net income (TTM)
−$51.20M
Trailing 12 months
Revenue growth YoY
+10.9%
Year over year
Operating margin
-141.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+8.3%
Year over year · more shares
Price change (1Y)
-60.1%
Trailing year
Short interest
1.7%
Latest settlement · 4.5 days to cover
AI Brief
Q2 FY26 earnings call · Aug 7, 2026
Q2 FY26
TL;DR. RPID reported Q2 revenue of $8.1M (+11% YoY) with record 15% gross margin, reaffirmed full-year 2026 revenue/placements/margin guidance, and raised full-year validation guidance to at least 27 systems.
Bullish
- + Q2 revenue of $8.1M grew 11% YoY and exceeded prior guidance
- + Reached milestone of 200th Growth Direct system placed globally
- + Delivered record 15% Q2 gross margin, up 11 percentage points YoY
- + Recurring revenue grew 14% YoY to $5M
- + Raised full-year 2026 validation guidance to at least 27 systems
- + Efficiency program expected to reduce expenses/cash usage by ~$1M in 2026 and ~$3M annually from 2027
Bearish
- − Product margin remained negative at -3% in Q2
- − Q2 net loss widened to $12.9M from $11.9M YoY
- − Adjusted EBITDA loss of $10.3M versus $10.1M YoY
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−54%
below
Price vs 50-day avg
−31%
below
RSI (14)
23
oversold
MACD trend
Negative
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−28%
trailing
6-month return
−48%
trailing
YTD return
−58%
this year
Relative strength
−66%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-28% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.73% of float · ▲ +3.0% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
33 holders — mid 3-yr range
Squeeze score
46
elevated · 0–100
Fundamentals
Revenue growth
+20%
Y/Y
EPS growth
+3%
Y/Y
Free cash flow
$-31.9M
Balance sheet
$27.1M
net cash
Quant / Vol
risk profile
Volatility
82%
annualized · 1-yr
Max drawdown
−74%
past year
ATR
9.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 7, 2026
Total revenue
· full year 2026
Initiated
$37M – $41M
prior FY $33.59M
midpoint +16.1% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−54%
Bearish
Price vs 50-day avg
−31%
Bearish
RSI (14)
23
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-28% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.73% of float · ▲ +3.0% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
33 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 1%
Range high $5
vs 200-day avg -54%
vs 50-day avg -31%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RPID
this stock
Rapid Micro Biosystems, Inc.
|
$61.70M | -57.6% | +19.7% | — | 1.7% |
|
ABT
Abbott Laboratories
|
$177.58B | -18.6% | +5.7% | 28.6 | 1.3% |
|
MDT
Medtronic plc
|
$116.35B | -5.3% | +8.4% | 22.4 | 0.9% |
|
SYK
Stryker Corp
|
$105.70B | -21.6% | +11.2% | 28.6 | 2.0% |
|
BSX
Boston Scientific Corp
|
$62.29B | -54.9% | +12.5% | 17.4 | 3.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RPID | -10.9% | -27.7% | -47.7% | -19.1% | -57.6% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -9.7% | -25.9% | -65.5% | -18.7% | -69.7% |
Key facts
CIK
1380106
CUSIP
75340L104
13F (30d)
14 filings
14 filers
Visit website
Investor relations